The Effects of Thiazolidinediones on Metabolic Complications and Lipodystrophy in HIV-Infected PatientsReport as inadecuate

The Effects of Thiazolidinediones on Metabolic Complications and Lipodystrophy in HIV-Infected Patients - Download this document for free, or read online. Document in PDF available to download.

PPAR ResearchVolume 2009 2009, Article ID 373524, 15 pages

Review ArticleDivision of Infectious Diseases and Division of Diabetes, Department of Medicine, Helsinki University Central Hospital, 00029 HUS, Helsinki, Finland

Received 18 March 2008; Accepted 25 August 2008

Academic Editor: Jacqueline Capeau

Copyright © 2009 Jussi Sutinen. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Highly active antiretroviral therapy HAART-associated metabolic complications include lipoatrophy loss of subcutaneous adipose tissue SAT and insulin resistance. Thiazolidinediones are insulin-sensitizing antidiabetic agents which—as an untoward side effect in obese diabetic patients—increase SAT. Furthermore, troglitazone has improved lipoatrophy and glycemic control in non-HIV patients with various forms of lipodystrophy. These data have led to 14 clinical trials to examine whether thiazolidinediones could be useful in the treatment of HAART-associated metabolic complications. The results of these studies indicate very modest, if any, effect on lipoatrophic SAT, probably due to ongoing HAART negating the beneficial effect. The benefit might be more prominent in patients not taking thymidine analoges. Despite the poor effect on lipoatrophy, thiazolidin-ediones improved insulin sensitivity. However, especially rosiglitazone induced harmful effects on blood lipids. Current data do not provide evidence for the use of thiazolidinediones in the treatment of HAART-associated lipoatrophy, but treatment of lipoatrophy-associated diabetes may be warranted. The role of thiazolidinediones for novel indications, such as hepatosteatosis, should be studied in these patients.

Author: Jussi Sutinen



Related documents